Finasteride /Proscar CAS 98319-26-7 Suplementos antiestrógenos para el tratamiento de la caída del cabello
Detalle rápido:
| nombre del producto |
Finasterida |
| Sinónimos |
PROSCAR;PROSTIDE;NORTE-(2-METHYL-2-PROPYL)-3-OXO-4-AZA-5ALPHA-ANDROST-1-ENE-17BETA-CARBOXAMIDE;MK-906;(5alfa,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-eno-17-carboxamide;17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one;4-azaandrost-1-ene-17-carboxamide,norte-(1,1-dimethylethyl)-3-oxo-,(5-alfa,17-ser;4-azaandrost-1-ene-17-carboxamide,norte-(1,1-dimethylethyl)-3-oxo-,(5alfa,17beta |
| NO CAS |
98319-26-7 |
| MF |
C23H36N2O2 |
| MW |
372.54 |
| Pureza |
>99% |
| Temperatura de almacenamiento |
-20° C Congelador |
| Propiedades químicas |
Off-White Crystalline Powder |
| Categorías de Producto |
Intermedios farmacéuticos |
| Tiempo de entrega |
Dentro de 3 work days upon receipt of payment |
| Envío |
EMS, DHL, TNT, FedEx, UPS |
| Usos |
Treatment of benign prostatic hyperplasia and androgenetic alopecia |
Agrandamiento de la próstata
Physicians sometimes use finasteride for the treatment of BPH, informalmente conocido como agrandamiento de la próstata. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 años) and the need for surgery (−54% at 4 años). If the drug is discontinued, any therapeutic benefits reverse within about 6-8 meses.
Pattern hair loss
Finasteride is sometimes used to treat pattern hair loss (alopecia androgenética) solo en hombres. Treatment slows further hair loss and provides about 30% Mejora de la caída del cabello después de seis meses de tratamiento., with effectiveness only persisting as long as the drug is taken. Finasteride has also been tested for pattern hair loss in women; the results were no better than placebo.
COA:
| Elementos de prueba |
Especificación |
Resultados de la prueba |
| Descripción |
Polvo cristalino blanco u blanco |
Polvo cristalino blanquecino |
| Rotacion especifica |
-56°~-60° |
-58.2° |
| Identificación |
Y |
Coincide con el estándar de trabajo |
Cumple |
| HPLC |
| Solubilidad |
Totalmente soluble en cloroformo y en alcohol.; Muy ligeramente soluble en agua |
Ajustarse |
| Metales pesados |
≤10 ppm |
<10 ppm |
| Agua |
≤0.3% |
0.22% |
| Residuos en ignición |
≤0.1% |
0.05% |
| Material relativo |
Maximum impurities≤0.5% |
0.36% |
| Impurezas totales ≤1.0% |
0.52% |
| Ensayo |
98.5~ 101.0% |
99.68% |
| Conclusión |
The specification conform with USP29
|